Advertisement
Advertisement
U.S. markets close in 4 hours 7 minutes
Advertisement
Advertisement
Advertisement
Advertisement

BioMarin Pharmaceutical Inc. (BMRN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
84.09+1.93 (+2.35%)
As of 11:52AM EDT. Market open.
Advertisement

BioMarin Pharmaceutical Inc.

770 Lindaro Street
San Rafael, CA 94901
United States
415 506 6700
https://www.biomarin.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees3,045

Key Executives

NameTitlePayExercisedYear Born
Mr. Jean-Jacques Bienaime M.B.A., MBAChairman & CEO3.67M8.16M1953
Mr. Brian R. MuellerExec. VP of Fin. & CFO1.13M343.97k1974
Dr. C. Greg Guyer Ph.D.CTO and Exec. VP of Global Manufacturing & Technical Operations1.75MN/A1962
Mr. Jeffrey Robert AjerExec. VP & Chief Commercial Officer1.2MN/A1962
Dr. Henry J. Fuchs M.D., Ph.D.Pres of Worldwide R&D1.52MN/A1958
Ms. Erin BurkhartGroup VP & Chief Accounting OfficerN/AN/AN/A
Traci McCartyVP of Investor RelationsN/AN/AN/A
Mr. George Eric DavisExec. VP, Gen. Counsel & Sec.N/AN/A1971
Mr. Philip Lo ScalzoSr. VP & Chief Compliance OfficerN/AN/AN/A
Ms. Humaira SerajuddinSr. VP & Chief Marketing OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Corporate Governance

BioMarin Pharmaceutical Inc.’s ISS Governance QualityScore as of September 1, 2022 is 5. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 5; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement